Biointron Launches RushData, an Integrated Platform for AI-Driven Antibody Discovery with 1-Day CHO Expression
1-day CHO expression for data generation in days, not weeks, for standardized, structured datasets ready for AI/ML-driven design
Custom workflows for targets and modalities, with 3,000+ molecules per batch processed in parallel
Identify liabilities early with developability assessments to reduce late-stage failure and downstream risk
Biointron Biological USA Inc. ("Biointron"), a leading contract research organization for antibody discovery, expression, and optimization, has launched RushData. RushData is an integrated service platform designed to support the growing demands of AI- and machine learning-driven antibody discovery for global pharma and biotech organizations.
